Publications Christian GAIDDON avant 2013

Miller, J. J., Orvain, C., Jozi, S., Clarke, R. M., Smith, J. R., Blanchet, A., Gaiddon, C., Warren, J. J., & Storr, T. (2018). Multifunctional Compounds for Activation of the p53-Y220C Mutant in Cancer. Chemistry (Weinheim an Der Bergstrasse, Germany), 24(67), 17734–17742.
Vidimar, V., Meng, X., Klajner, M., Licona, C., Fetzer, L., Harlepp, S., Hébraud, P., Sidhoum, M., Sirlin, C., Loeffler, J.-P., Mellitzer, G., Sava, G., Pfeffer, M., & Gaiddon, C. (2012). Induction of caspase 8 and reactive oxygen species by ruthenium-derived anticancer compounds with improved water solubility and cytotoxicity. Biochemical Pharmacology, 84(11), 1428–1436.
Ribeiro, N., Thuaud, F., Bernard, Y., Gaiddon, C., Cresteil, T., Hild, A., Hirsch, E. C., Michel, P. P., Nebigil, C. G., & Désaubry, L. (2012). Flavaglines as potent anticancer and cytoprotective agents. Journal of Medicinal Chemistry, 55(22), 10064–10073.
Bergamo, A., Gaiddon, C., Schellens, J. H. M., Beijnen, J. H., & Sava, G. (2012). Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates. Journal of Inorganic Biochemistry, 106(1), 90–99.
Benosman, S., Meng, X., Von Grabowiecki, Y., Palamiuc, L., Hritcu, L., Gross, I., Mellitzer, G., Taya, Y., Loeffler, J.-P., & Gaiddon, C. (2011). Complex regulation of p73 isoforms after alteration of amyloid precursor polypeptide (APP) function and DNA damage in neurons. The Journal of Biological Chemistry, 286(50), 43013–43025.
Fetzer, L., Boff, B., Ali, M., Xiangjun, M., Collin, J.-P., Sirlin, C., Gaiddon, C., & Pfeffer, M. (2011). Library of second-generation cycloruthenated compounds and evaluation of their biological properties as potential anticancer drugs: passing the nanomolar barrier. Dalton Transactions (Cambridge, England: 2003), 40(35), 8869–8878.
Thuaud, F., Ribeiro, N., Gaiddon, C., Cresteil, T., & Désaubry, L. (2011). Novel flavaglines displaying improved cytotoxicity. Journal of Medicinal Chemistry, 54(1), 411–415.
Klajner, M., Hebraud, P., Sirlin, C., Gaiddon, C., & Harlepp, S. (2010). DNA binding to an anticancer organo-ruthenium complex. The Journal of Physical Chemistry. B, 114(44), 14041–14047.
Meng, X., Leyva, M. L., Jenny, M., Gross, I., Benosman, S., Fricker, B., Harlepp, S., Hébraud, P., Boos, A., Wlosik, P., Bischoff, P., Sirlin, C., Pfeffer, M., Loeffler, J.-P., & Gaiddon, C. (2009). A ruthenium-containing organometallic compound reduces tumor growth through induction of the endoplasmic reticulum stress gene CHOP. Cancer Research, 69(13), 5458–5466.
Ohtsubo, C., Shiokawa, D., Kodama, M., Gaiddon, C., Nakagama, H., Jochemsen, A. G., Taya, Y., & Okamoto, K. (2009). Cytoplasmic tethering is involved in synergistic inhibition of p53 by Mdmx and Mdm2. Cancer Science, 100(7), 1291–1299.
Benosman, S., Gross, I., Clarke, N., Jochemsen, A. G., Okamoto, K., Loeffler, J.-P., & Gaiddon, C. (2007). Multiple neurotoxic stresses converge on MDMX proteolysis to cause neuronal apoptosis. Cell Death and Differentiation, 14(12), 2047–2057.
Gross, I., Armant, O., Benosman, S., de Aguilar, J. L. G., Freund, J.-N., Kedinger, M., Licht, J. D., Gaiddon, C., & Loeffler, J.-P. (2007). Sprouty2 inhibits BDNF-induced signaling and modulates neuronal differentiation and survival. Cell Death and Differentiation, 14(10), 1802–1812.
Lokshin, M., Li, Y., Gaiddon, C., & Prives, C. (2007). p53 and p73 display common and distinct requirements for sequence specific binding to DNA. Nucleic Acids Research, 35(1), 340–352.
Gross, I., Lhermitte, B., Domon-Dell, C., Duluc, I., Martin, E., Gaiddon, C., Kedinger, M., & Freund, J.-N. (2005). Phosphorylation of the homeotic tumor suppressor Cdx2 mediates its ubiquitin-dependent proteasome degradation. Oncogene, 24(54), 7955–7963.
Gaiddon, C., Jeannequin, P., Bischoff, P., Pfeffer, M., Sirlin, C., & Loeffler, J. P. (2005). Ruthenium (II)-derived organometallic compounds induce cytostatic and cytotoxic effects on mammalian cancer cell lines through p53-dependent and p53-independent mechanisms. The Journal of Pharmacology and Experimental Therapeutics, 315(3), 1403–1411.
Di Scala, F., Dupuis, L., Gaiddon, C., De Tapia, M., Jokic, N., Gonzalez de Aguilar, J.-L., Raul, J.-S., Ludes, B., & Loeffler, J.-P. (2005). Tissue specificity and regulation of the N-terminal diversity of reticulon 3. The Biochemical Journal, 385(Pt 1), 125–134.
Gaiddon, C., Lokshin, M., Gross, I., Levasseur, D., Taya, Y., Loeffler, J.-P., & Prives, C. (2003). Cyclin-dependent kinases phosphorylate p73 at threonine 86 in a cell cycle-dependent manner and negatively regulate p73. The Journal of Biological Chemistry, 278(30), 27421–27431.
Gaiddon, C., Lokshin, M., Ahn, J., Zhang, T., & Prives, C. (2001). A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Molecular and Cellular Biology, 21(5), 1874–1887.
González de Aguilar, J. L., Gordon, J. W., René, F., de Tapia, M., Lutz-Bucher, B., Gaiddon, C., & Loeffler, J. P. (2000). Alteration of the Bcl-x/Bax ratio in a transgenic mouse model of amyotrophic lateral sclerosis: evidence for the implication of the p53 signaling pathway. Neurobiology of Disease, 7(4), 406–415.
Gaiddon, C., Moorthy, N. C., & Prives, C. (1999). Ref-1 regulates the transactivation and pro-apoptotic functions of p53 in vivo. The EMBO Journal, 18(20), 5609–5621.
Gaiddon, C., Larmet, Y., Trinh, E., Boutillier, A. L., Sommer, B., & Loeffler, J. P. (1999). Brain-derived neurotrophic factor exerts opposing effects on beta2-adrenergic receptor according to depolarization status of cerebellar neurons. Journal of Neurochemistry, 73(4), 1467–1476.
Gaiddon, C., de Tapia, M., & Loeffler, J. P. (1999). The tissue-specific transcription factor Pit-1/GHF-1 binds to the c-fos serum response element and activates c-fos transcription. Molecular Endocrinology (Baltimore, Md.), 13(5), 742–751.
Sohm, F., Gaiddon, C., Antoine, M., Boutillier, A. L., & Loeffler, J. P. (1999). The retinoblastoma susceptibility gene product/Sp1 signalling pathway is modulated by Ca2+/calmodulin kinases II and IV activity. Oncogene, 18(17), 2762–2769.
Di Como, C. J., Gaiddon, C., & Prives, C. (1999). p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Molecular and Cellular Biology, 19(2), 1438–1449.
Boutillier, A. L., Gaiddon, C., Lorang, D., Roberts, J. L., & Loeffler, J. P. (1998). Transcriptional activation of the proopiomelanocortin gene by cyclic AMP-responsive element binding protein. Pituitary, 1(1), 33–43.
Cabot, P. J., Carter, L., Gaiddon, C., Zhang, Q., Schäfer, M., Loeffler, J. P., & Stein, C. (1997). Immune cell-derived beta-endorphin. Production, release, and control of inflammatory pain in rats. The Journal of Clinical Investigation, 100(1), 142–148.
René, F., Monnier, D., Gaiddon, C., Félix, J. M., & Loeffler, J. P. (1996). Pituitary adenylate cyclase-activating polypeptide transduces through cAMP/PKA and PKC pathways and stimulates proopiomelanocortin gene transcription in mouse melanotropes. Neuroendocrinology, 64(1), 2–13.
Antoine, M., Gaiddon, C., & Loeffler, J. P. (1996). Ca2+/calmodulin kinase types II and IV regulate c-fos transcription in the AtT20 corticotroph cell line. Molecular and Cellular Endocrinology, 120(1), 1–8.
Gaiddon, C., Loeffler, J. P., & Larmet, Y. (1996). Brain-derived neurotrophic factor stimulates AP-1 and cyclic AMP-responsive element dependent transcriptional activity in central nervous system neurons. Journal of Neurochemistry, 66(6), 2279–2286.
Gaiddon, C., Tian, J., Loeffler, J. P., & Bancroft, C. (1996). Constitutively active G(S) alpha-subunits stimulate Pit-1 promoter activity via a protein kinase A-mediated pathway acting through deoxyribonucleic acid binding sites both for Pit-1 and for adenosine 3’,5’-monophosphate response element-binding protein. Endocrinology, 137(4), 1286–1291.
Gaiddon, C., Mercken, L., Bancroft, C., & Loeffler, J. P. (1995). Transcriptional effects in GH3 cells of Gs alpha mutants associated with human pituitary tumors: stimulation of adenosine 3’,5’-monophosphate response element-binding protein-mediated transcription and of prolactin and growth hormone promoter activity via protein kinase A. Endocrinology, 136(10), 4331–4338.
Gaiddon, C., Boutillier, A. L., Monnier, D., Mercken, L., & Loeffler, J. P. (1994). Genomic effects of the putative oncogene G alpha s. Chronic transcriptional activation of the c-fos proto-oncogene in endocrine cells. The Journal of Biological Chemistry, 269(36), 22663–22671.